Tectonic Therapeutic, Inc. (NASDAQ:TECX – Get Free Report) insider Marcella Ruddy sold 1,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $31.05, for a total value of $31,050.00. Following the transaction, the insider directly owned 68,747 shares of the company’s stock, valued at $2,134,594.35. The trade was a 1.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Tectonic Therapeutic Price Performance
TECX stock remained flat at $30.52 during midday trading on Friday. 163,056 shares of the company’s stock were exchanged, compared to its average volume of 310,637. The company’s 50-day moving average is $26.11 and its 200-day moving average is $21.13. The company has a market cap of $573.17 million, a P/E ratio of -7.54 and a beta of 3.59. Tectonic Therapeutic, Inc. has a fifty-two week low of $13.70 and a fifty-two week high of $36.03.
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. As a group, analysts anticipate that Tectonic Therapeutic, Inc. will post -8.31 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities research analysts recently weighed in on TECX shares. Lifesci Capital upgraded Tectonic Therapeutic to a “strong-buy” rating in a report on Thursday, February 5th. Truist Financial decreased their target price on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tectonic Therapeutic presently has an average rating of “Moderate Buy” and an average target price of $81.50.
Get Our Latest Research Report on Tectonic Therapeutic
Tectonic Therapeutic Company Profile
Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Recommended Stories
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
